Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
11/2003
11/26/2003EP1363704A2 Dapd combination therapy with inosine monophosphate dehydrogenase inhibitor
11/26/2003EP1363677A1 Method of using a variant of vegf receptor to treat psoriasis and to enhance wound healing
11/26/2003EP1363674A2 Agents and methods for treating pain
11/26/2003EP1363669A2 Method of using a cyclooxygenase-2 inhibitor and sex steroids as a combination therapy for the treatment and prevention of dismenorrhea
11/26/2003EP1363668A2 Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications
11/26/2003EP1363657A2 Method for promoting neovascularization using a tweak agonist and an angiogenic factor
11/26/2003EP1363653A2 Methods and compositions for enhancing angiogenesis
11/26/2003EP1363644A2 Modulation of gsk-3beta activity and its different uses
11/26/2003EP1363636A1 A method for the treatment of heart failure
11/26/2003EP1363635A1 Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
11/26/2003EP1363627A2 Treatment of solid tumours with rapamycin derivatives
11/26/2003EP1363622A1 Pharmaceutical compositions including sampatrilat dispersed in a lipoidic vehicle
11/26/2003EP1363619A2 Coumarin compounds as microtubule stabilizing agents and therapeutic uses thereof
11/26/2003EP1363618A1 Pharmaceutical composition for treating multiple sclerosis
11/26/2003EP1363613A2 Use of rhein for preparing a medicine for treating a high rate of il-1
11/26/2003EP1363610A2 Carotenoids as anti-hypertension agents
11/26/2003EP1363606A1 Use of gaba[a] inverse agonists in combination with nicotine receptor partial agonists, estrogen, selective estrogen modulators or vitamin e for the treatment of coginitive disorders
11/26/2003EP1363604A2 Pharmaceutical formulation
11/26/2003EP1363550A2 A compound and method of treatment for fungal pathologies of the oral cavity
11/26/2003EP1363528A2 Methods for diagnosing and treating heart disease
11/26/2003EP1301196B1 Stimulation of bone growth with thrombin peptide derivatives
11/26/2003EP0912601B1 Suppression of immune response via inhibition of cathepsin s
11/26/2003EP0888123B1 Antagonism of endothelin actions
11/26/2003EP0871492B1 Mesothelium antigen and methods and kits for targeting it
11/26/2003EP0828487B1 Agents for use against parasitic protozoa
11/26/2003EP0814813B1 Use of penciclovir for the treatment of human herpes-virus-8
11/26/2003EP0705278B1 Apoptose inhibitor
11/26/2003CN1458979A Modulating multiple lineage kinase proteins
11/26/2003CN1458974A Stimulation of cartilage growth with agonists of non-protecolytically activated thrombin receptor
11/26/2003CN1458923A Substituted amino-aza-cycloalkanes useful against malaria
11/26/2003CN1458850A Peritoneal dialysates and its preparing method
11/26/2003CN1458847A Preparation for enhancement of action of anti-infective agent and method
11/26/2003CN1458841A Use of matrix metalloprotease ihibitors for treatment of cancer
11/26/2003CN1458840A Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
11/26/2003CN1457902A Method for influencing sleep and relative activity to sleep
11/26/2003CN1457768A Compound tablet capable of controlling release of effective component after oral administration
11/26/2003CN1128618C Use of histamine for elevating blood histamine
11/26/2003CN1128613C Combination of progresterone antagonists and anti-oestrogens with partial agonistic action for use in hormone-replacement therapy for perio- and post menopansal woman
11/25/2003US6653479 Crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b] thiophene hydrochloride
11/25/2003US6653466 Active principle comprises antisense oligonucleotide consisting of a 20 to 50-nucleotide sequence against exon 19 of dystrophin pre-mRNA
11/25/2003US6653446 Nucleotide sequences which code enzymatic polypeptide for use in treatment of gout, kidney, blood and preferential genetic disorders
11/25/2003US6653445 Chemotactic cytokine V (CCV); isolated protein of given sequence; use in diagnostics and as anti-viral or anti-tumor agent
11/25/2003US6653382 Ethylene-unsaturated carboxylic acid copolymer; ionomers; resilience, melt processability
11/25/2003US6653352 Pain reliever and method of use
11/25/2003US6653351 Adjuvant chemotherapy for anaplastic gliomas
11/25/2003US6653350 Methods of treating osteoarthritis with inducible nitric oxide synthase inhibitors
11/25/2003US6653341 Using halichondrin B analog in combined therapy
11/25/2003US6653336 Combination of hypertensin converting enzyme inhibitor with a diuretic for treating microcirculation disorders
11/25/2003US6653332 Combination therapeutic compositions and method of use
11/25/2003US6653325 Dyskinesias, by administering a substituted phenylazacycloalkane and a dopamine agonist to the patient
11/25/2003US6653322 Therapeutic combinations of RAR antagonists and RXR agonists and use thereof
11/25/2003US6653317 2-amino-4-alkylamino-6-alkoxypyrimidine 3-oxides
11/25/2003US6653315 Substituted 5-amino-imidazolo-(4,3-e)-1,2,4-triazolo(1,5-c)-pyrimidines; central nervous system diseases; Parkinson's disease
11/25/2003US6653306 Epoxy-steroidal aldosterone antagonist and angiotensin II antagonist combination therapy
11/25/2003US6653304 Antiarthritic agents; skin disorders; anticarcinogenic agents
11/25/2003US6653301 For therapy of cancer, diabetes and Alzheimer's disease
11/25/2003US6653300 Pyrazole compounds useful as protein kinase inhibitors
11/25/2003US6653293 Administering substance stimulating infected cells to increase HIV replication; causing extracorporeal apoptosis and reinfusing blood
11/25/2003US6653292 Stimulating Th1 pattern of immune activation, cytokine production, NK lytic activity and B cell proliferation; modulating with nucleic acid sequences containing unmethylated CpG dinucleotides
11/25/2003US6653285 Polypeptide inhibitors and enhancers of glycosaminoglycans such as hyaluronic acid, chondroitin sulfate, dermatan sulfate, heparin, keratan sulfate, chitin and chitosans; antiinflammatory and anticarcinogenic agents; infections
11/25/2003US6653116 Peptide for use in the treatment of inflammation, cancer, arteriosclerosis and psoriasis
11/25/2003US6653094 Diagnosing pancreatic defect in humans; obtain organelle sample, detect preferential organelle, monitor sample for organelle defect, diagnose pancreatic defect
11/25/2003US6652890 Treating cancer cells that express a membrane protein tNOX, a hormone-insensitive and drug-responsive form of NOX (NADH oxidase) specific to cancer cells
11/25/2003US6652873 Compositions and methods for enhancing receptor-mediated cellular internalization
11/25/2003US6652855 Treatment of LFA-1 associated disorders with increasing doses of LFA-1 antagonist
11/25/2003US6652854 Administering agents that hinder CD30/CD30L (CD30L=ligand of CD30) binding; animal model of arthritis for drug screening
11/25/2003US6652853 Useful for treating patients with colorectal cancer and gastric carcinomas; particularly useful for treating patients who have tumors that are resistant to one or more chemotherapeutic agents and/or have metastasized.
11/25/2003US6652840 Aluminum chloride, ferric sulfate, regenerated oxidized cellulose, aluminum ammonium sulfate, absorbable gelatin and solvent; easy to use; reducing heart rate stimulation, staining, acid irritations and adhesive interference
11/25/2003US6651816 Antihistamine/decongestant regimens for treating rhinitis
11/25/2003CA2258811C Formulation for use in the prevention of pathogen induced diseases including hiv and hsv
11/22/2003CA2429387A1 Compositions for providing vitamin d year round and uses thereof
11/21/2003CA2428112A1 Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasia
11/20/2003WO2003095971A2 Posh nucleic acids, polypeptides and related methods
11/20/2003WO2003095678A1 Ldl receptor-related proteins 1 and 2 and treatment of bone or cartilage conditions
11/20/2003WO2003095667A2 Autoimmune conditions and nadph oxidase defects
11/20/2003WO2003095662A2 Simultaneous detection of two analytes produced by a cell under the influence of a putative agent using a pin coated assay system
11/20/2003WO2003095621A2 Apoptotic ebv-transformed lymphocytes, a therapeutic agent for post-transplant lymphoproliferactive disorder
11/20/2003WO2003095613A2 Nucleic acids, polypeptides, and methods for modulating apoptosis
11/20/2003WO2003095455A2 Substituted pyrazolopyrimidines
11/20/2003WO2003095451A1 Carbamate-substituted pyrazolopyridines
11/20/2003WO2003095436A1 Benzoisoselenazole derivatives with anti-inflammation, antivirus and anti-thrombosis activity and their use
11/20/2003WO2003094991A1 Medical products comprising a haemocompatible coating, production and use thereof
11/20/2003WO2003094990A1 Compounds and method for coating surfaces in a haemocompatible manner
11/20/2003WO2003094969A1 Methods and compositions for treating tinea versicolor using combinations of retinoids and certain antifungals
11/20/2003WO2003094968A2 Combination of a proton pump inhibitor and a respiratory agent for the treatment of respiratory diseases
11/20/2003WO2003094967A2 New combination of reversible proton pump inhibitors and airway therapeutics for treating airway disorders
11/20/2003WO2003094966A1 Arterialization agent and antiarterialization agent
11/20/2003WO2003094957A2 Methods of therapy for inducing tolerance
11/20/2003WO2003094952A1 Intratumorally administered lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases
11/20/2003WO2003094924A1 Combination therapy for treating cyclooxygenase-2 mediated diseases in patients at risk of thrombotic cardiovascular events
11/20/2003WO2003094923A1 COMBINATION OF AN HMG-CoA REDUCTASE INHIBITOR AND A NITRATE ESTER
11/20/2003WO2003094920A1 Microbicidal pyrimidine or triazine for preventing sexual hiv transmission
11/20/2003WO2003094915A1 Use of valsartan ot its metabolite to inhibit platelet aggregation
11/20/2003WO2003094909A2 Methods and compositions for the treatment and prevention of intermittent claudication or alzheimer's disease
11/20/2003WO2003094904A1 Methods and compositions for the treatment of graft failure
11/20/2003WO2003094894A1 Nanoparticulate nystatin formulations
11/20/2003WO2003094888A1 Processes for forming a drug delivery device
11/20/2003WO2003094878A1 Gallocatechin gallate-containing composition
11/20/2003WO2003094859A2 Epha2 monoclonal antibodies and methods of use thereof
11/20/2003WO2003094856A2 1l1rl-1 as a cardiovascular disease marker and therapeutic target
1 ... 642 643 644 645 646 647 648 649 650 651 652 653 654 655 656 657 658 659 660 661 662 ... 1151